Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension

Ambrisentan for Pulmonary Arterial Hypertension Due to Congenital Heart Disease

(2011) Warren A. Zuckerman et al.   AMERICAN JOURNAL OF CARDIOLOGY

Safety and Efficacy of Ambrisentan for the Treatment of Portopulmonary Hypertension

(2010) Rodrigo Cartin-Ceba et al.   CHEST

Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study

(2009) Maurice Beghetti et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers

(2009) Gennyne Walker et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension

(2009) Martha Kingman et al.   EXPERT OPINION ON PHARMACOTHERAPY

Long-Term Outcomes With Ambrisentan Monotherapy in Pulmonary Arterial Hypertension

(2009) Shannon E. Blalock et al.   JOURNAL OF CARDIAC FAILURE

Ambrisentan for the Treatment of Pulmonary Arterial Hypertension

(2008) Nazzareno Galiè et al.   CIRCULATION

Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?

(2008) Christian F. Opitz et al.   EUROPEAN HEART JOURNAL

Pharmacokinetics and Safety of Ambrisentan in Combination With Sildenafil in Healthy Volunteers

(2008) Rebecca Spence et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects

(2008) Rebecca E. Wrishko et al.   JOURNAL OF CLINICAL PHARMACOLOGY